Patient characteristic, treatment and outcomes in metastatic Castration Resistant Prostate Cancer (mCRPC) in Finland

被引:0
|
作者
Rannikko, A. S. [1 ,2 ]
Agesen, T. [3 ]
Holsa, O. [4 ]
Tuominen, S. [4 ]
Hanssen, J. [5 ]
Mattila, R. [4 ]
机构
[1] Univ Helsinki, Dept Urol, Helsinki, Finland
[2] Helsinki Univ Hosp, Dept Urol, Helsinki, Finland
[3] AstraZeneca, Dept Nord, Oslo, Norway
[4] Medaffcon Oy, RWE, Espoo, Finland
[5] AstraZeneca, Dept Nord, Copenhagen, Denmark
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A1189
引用
收藏
页数:2
相关论文
共 50 条
  • [1] HEALTHCARE RESOURCE USE AND COST IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) IN FINLAND
    Rannikko, A.
    Agesen, T.
    Holsa, O.
    Tuominen, S.
    Ekman, M.
    Mattila, R.
    VALUE IN HEALTH, 2023, 26 (12) : S66 - S67
  • [2] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [3] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafetris
    Mateo, Joaquin
    De Bono, Johann S.
    MODERN PATHOLOGY, 2016, 29 : 251A - 251A
  • [4] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafeiris
    Mateo, Joaquin
    De Bono, Johann S.
    LABORATORY INVESTIGATION, 2016, 96 : 251A - 251A
  • [5] UTILIZING INDIRECT TREATMENT COMPARISONS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Wasiak, R.
    Joulain, F.
    Lambrelli, D.
    Trask, P. C.
    Sartor, O.
    VALUE IN HEALTH, 2012, 15 (07) : A475 - A476
  • [6] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Patient preferences for the treatment of metastatic castration-resistant prostate cancer in Australia (mCRPC): A discrete choice experiment
    Winnall, Wendy R.
    Winkler, Karen
    Godsell, Jenni
    Axford, Laurie
    Xhilaga, Miranda
    Fifer, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 212 - 212
  • [9] Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Gamat-Huber, Melissa
    Jeon, Donghwan
    Johnson, Laura E.
    Moseman, Jena E.
    Muralidhar, Anusha
    Potluri, Hemanth K.
    Rastogi, Ichwaku
    Wargowski, Ellen
    Zahm, Christopher D.
    McNeel, Douglas G.
    CANCERS, 2020, 12 (10) : 1 - 23
  • [10] Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
    Lumen, Nicolaas
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    Thoret-Bauchet, Florence
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35